

PubMed

Display Settings:  Abstract

Oncogene. 2011 Sep 12. doi: 10.1038/onc.2011.398. [Epub ahead of print]

## Standard of care therapy for malignant glioma and its effect on tumor and stromal cells.

Jones TS, Holland EC.

1] Department of Clinical Pharmacy, University of Tennessee Health Science Center, Memphis, TN, USA [2] Department of Neurosurgery, University of Tennessee Health Science Center, Memphis, TN, USA [3] Center for Cancer Research, University of Tennessee Health Science Center, Memphis, TN, USA.

### Abstract

Glioblastoma is the most common and deadly of the primary central nervous system tumors. Recent advances in molecular characterization have subdivided these tumors into at least three main groups. In addition, these tumors are cellularly complex with multiple stromal cell types contributing to the biology of the tumor and treatment response. Because essentially all glioma patients are treated with radiation, various chemotherapies and steroids, the tumor that finally kills them has been modified by these treatments. Most of the investigation of the effects of therapy on these tumors has focused on the glioma cells per se. However, despite the importance of the stromal cells in these tumors, little has been done to understand the effects of treatment on stromal cells and their contribution to disease. Understanding how current standard therapy affects the biology of the tumor and the tumor stroma may provide insight into the mechanisms that are important to the inhibition of tumor growth as well as the biology of recurrent tumors. *Oncogene* advance online publication, 12 September 2011; doi:10.1038/onc.2011.398.

PMID: 21909136 [PubMed - as supplied by publisher]

[+](#) **LinkOut - more resources**